Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinoma In Situ post-lumpectomy.

IF 5.9 2区 医学 Q1 IMMUNOLOGY
Frontiers in Immunology Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI:10.3389/fimmu.2025.1681072
Yupeng Sha, Quan Yuan, Yi Du, Shuqi Yang, Ming Niu, Xiaoshuan Liang, Shanshan Sun, Tong Li, Shu Gong, Jiguang Han
{"title":"Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinoma <i>In Situ</i> post-lumpectomy.","authors":"Yupeng Sha, Quan Yuan, Yi Du, Shuqi Yang, Ming Niu, Xiaoshuan Liang, Shanshan Sun, Tong Li, Shu Gong, Jiguang Han","doi":"10.3389/fimmu.2025.1681072","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In women with ductal carcinoma <i>in situ</i> (DCIS) undergoing breast-conserving surgery, still part will progress to invasive breast cancer (IBC) in the future. Mammograms offer rich tumor data for patient stratification, but current prediction methods focus on clinicopathological factors, overlooking imaging insights.</p><p><strong>Methods: </strong>We retrospectively analyzed 140 DCIS patients from Harbin Medical University Cancer Hospital (2011-2020, followed up to 2025). Preoperative digital mammograms and clinicopathological data were collected, with mammographic features extracted using pyradiomics and supervised by a senior radiologist. Feature selection employed 10-fold cross-validated LASSO regression. The dataset was split into training (n=100) and validation (n=40) sets (10:4 ratio). Sixteen machine learning algorithms combining mammographic deep learning features and clinicopathological variables were developed and compared for predicting DCIS recurrence. Model performance was assessed using ROC, sensitivity, specificity, PPV, NPV, and SHAP values for interpretation.</p><p><strong>Results: </strong>The Gradient Boosting Machine (GBM) algorithm had the best predictive performance, with an AUC of 0.918 (95% CI 0.873-0.963) in the test set. SHAP values indicated that the mammographic signature (MS) was the most significant predictor, followed by Ki-67 index and histological grade. Patients not receiving radiotherapy had higher recurrence rates than those who did. Decision curve analysis validated the model's clinical utility across various risk thresholds.</p><p><strong>Conclusion: </strong>Our study developed an interpretable GBM model incorporating mammographic and clinical data to predict DCIS recurrence (AUC = 0.918). Key predictors were mammographic signature, Ki-67, and tumor grade, offering clinicians a practical tool for personalized postoperative management.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1681072"},"PeriodicalIF":5.9000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477132/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2025.1681072","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In women with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery, still part will progress to invasive breast cancer (IBC) in the future. Mammograms offer rich tumor data for patient stratification, but current prediction methods focus on clinicopathological factors, overlooking imaging insights.

Methods: We retrospectively analyzed 140 DCIS patients from Harbin Medical University Cancer Hospital (2011-2020, followed up to 2025). Preoperative digital mammograms and clinicopathological data were collected, with mammographic features extracted using pyradiomics and supervised by a senior radiologist. Feature selection employed 10-fold cross-validated LASSO regression. The dataset was split into training (n=100) and validation (n=40) sets (10:4 ratio). Sixteen machine learning algorithms combining mammographic deep learning features and clinicopathological variables were developed and compared for predicting DCIS recurrence. Model performance was assessed using ROC, sensitivity, specificity, PPV, NPV, and SHAP values for interpretation.

Results: The Gradient Boosting Machine (GBM) algorithm had the best predictive performance, with an AUC of 0.918 (95% CI 0.873-0.963) in the test set. SHAP values indicated that the mammographic signature (MS) was the most significant predictor, followed by Ki-67 index and histological grade. Patients not receiving radiotherapy had higher recurrence rates than those who did. Decision curve analysis validated the model's clinical utility across various risk thresholds.

Conclusion: Our study developed an interpretable GBM model incorporating mammographic and clinical data to predict DCIS recurrence (AUC = 0.918). Key predictors were mammographic signature, Ki-67, and tumor grade, offering clinicians a practical tool for personalized postoperative management.

将乳房x线摄影的深度学习特征与SHAP值相结合,构建预测乳房肿瘤切除术后原位乳腺导管癌5年复发的机器学习模型。
背景:在接受保乳手术的导管原位癌(DCIS)患者中,仍有一部分会在未来发展为浸润性乳腺癌(IBC)。乳房x线照片为患者分层提供了丰富的肿瘤数据,但目前的预测方法侧重于临床病理因素,忽视了影像学的见解。方法:回顾性分析哈尔滨医科大学肿瘤医院2011-2020年,随访至2025年的140例DCIS患者。收集术前数字乳房x线照片和临床病理数据,并在高级放射科医生的监督下使用放射组学提取乳房x线照片特征。特征选择采用10倍交叉验证LASSO回归。数据集被分成训练集(n=100)和验证集(n=40)(比例为10:4)。结合乳房x线摄影深度学习特征和临床病理变量,开发了16种机器学习算法,并对预测DCIS复发进行了比较。使用ROC、敏感性、特异性、PPV、NPV和SHAP值来评估模型的性能。结果:梯度增强机(Gradient Boosting Machine, GBM)算法预测效果最好,在测试集中AUC为0.918 (95% CI 0.873 ~ 0.963)。SHAP值显示乳房x线摄影特征(MS)是最显著的预测因子,其次是Ki-67指数和组织学分级。未接受放疗的患者复发率高于接受放疗的患者。决策曲线分析验证了该模型跨越各种风险阈值的临床效用。结论:我们的研究建立了一个可解释的GBM模型,结合乳房x线摄影和临床数据来预测DCIS复发(AUC = 0.918)。关键的预测指标是乳房x线摄影特征、Ki-67和肿瘤分级,为临床医生提供了个性化术后管理的实用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.80
自引率
11.00%
发文量
7153
审稿时长
14 weeks
期刊介绍: Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信